Jessica C Hassel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1233150/publications.pdf Version: 2024-02-01



IFSSICA C HASSEL

#	Article	IF	CITATIONS
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	2.8	28
2	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. , 2022, 10, e003198.		21
3	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 2022, 14, 518.	3.7	6
4	TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. Cancers, 2022, 14, 1215.	3.7	8
5	Targeted Therapy for Melanomas Without BRAF V600 Mutations. Current Treatment Options in Oncology, 2022, 23, 831-842.	3.0	8
6	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 2022, 14, 1804.	3.7	4
7	Tebentafusp for the treatment of metastatic uveal melanoma. Future Oncology, 2022, 18, 1303-1311.	2.4	1
8	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. European Journal of Cancer, 2022, 166, 24-32.	2.8	10
9	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. European Journal of Cancer, 2022, 166, 60-72.	2.8	7
10	Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. Cancer Immunology, Immunotherapy, 2022, 71, 2051-2056.	4.2	10
11	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Oncolmmunology, 2022, 11, 2066609.	4.6	13
12	Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Strahlentherapie Und Onkologie, 2022, 198, 884-891.	2.0	2
13	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	2.5	2
14	Four cases of erysipelasâ€ŀike inflammation in patients with metastatic melanoma treated with checkpoint inhibitors. JDDG - Journal of the German Society of Dermatology, 2021, 19, 598-602.	0.8	1
15	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncolmmunology, 2021, 10, 1926762.	4.6	32
16	Generalized perforating granuloma annulare: a case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 585-587.	0.8	1
17	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers, 2021, 13, 1019.	3.7	12
18	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. Life, 2021, 11, 269.	2.4	7

#	Article	IF	CITATIONS
19	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials, 2021, 22, 294.	1.6	1
20	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	2.8	40
21	Multiple alopecic patches in the hairy scalp area of a 28â€yearâ€old female patient. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1222-1224.	0.8	0
22	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	10.7	37
23	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 2021, 149, 37-48.	2.8	12
24	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	2.8	10
25	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	2.8	2
26	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	3.7	8
27	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	2.8	15
28	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers, 2021, 13, 2319.	3.7	15
29	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MC/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	10.7	224
30	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	2.8	13
31	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. European Journal of Cancer, 2021, 152, 41-48.	2.8	18
32	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq0	0 0 rgBT /0	Dverlock 10 T
33	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 2021, 13, 3359.	3.7	18
34	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. Cancer Research, 2021, 81, CT002-CT002.	0.9	10
35	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Research, 2021, 11, 89.	2.5	15
_			

³⁶Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of
Medicine, 2021, 385, 1196-1206.27.0376

#	Article	IF	CITATIONS
37	Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. Immunotherapy, 2021, 13, 1079-1083.	2.0	2
38	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	6.4	17
39	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
40	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. Cancers, 2021, 13, 5170.	3.7	1
41	Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma. British Journal of Cancer, 2021, , .	6.4	1
42	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	2.8	10
43	546â€Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). , 2021, 9, A576-A576.		3
44	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. Life, 2021, 11, 1318.	2.4	7
45	549â€An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion. , 2021, 9, A579-A579.		2
46	538â€Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
47	Cerebral metastases of a dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2020, 18, 143-145.	0.8	0
48	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 2020, 182, 1252-1270.e34.	28.9	259
49	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	1.6	119
50	Positron Emission Tomography in Merkel Cell Carcinoma. Cancers, 2020, 12, 2897.	3.7	9
51	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
52	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. European Journal of Cancer, 2020, 138, 125-132.	2.8	44
53	Melanoma brain metastases – Interdisciplinary management recommendations 2020. Cancer Treatment Reviews, 2020, 89, 102083	7.7	52
54	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	27.8	526

#	Article	IF	CITATIONS
55	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers, 2020, 12, 3004.	3.7	3
56	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. Frontiers in Oncology, 2020, 10, 592796.	2.8	10
57	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	2.4	2
58	Human innate immune cell crosstalk induces melanoma cell senescence. OncoImmunology, 2020, 9, 1808424.	4.6	5
59	Pleomorphic dermal sarcoma with cerebral metastasis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 886-888.	0.8	0
60	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 395, 1558-1568.	13.7	188
61	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. Journal of Clinical Medicine, 2020, 9, 1438.	2.4	11
62	Side effect management during immune checkpoint blockade using CTLAâ€4 and PDâ€1 antibodies for metastatic melanoma – an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.	0.8	24
63	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. American Journal of Hematology, 2020, 95, 1158-1169.	4.1	25
64	"UniCAR―modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports, 2020, 10, 2141.	3.3	62
65	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2257-2267.	7.0	39
66	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunology, Immunotherapy, 2020, 69, 1823-1832.	4.2	19
67	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
68	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301.	7.0	46
69	Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.		0
70	Clinical significance of signs of autoimmune colitis in ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy, 2019, 11, 667-676.	2.0	41
71	5-year results for pembrolizumab treatment of advanced melanoma. Lancet Oncology, The, 2019, 20, 1187-1189.	10.7	5
72	Immunotherapies for the Treatment of Uveal Melanoma—History and Future. Cancers, 2019, 11, 1048.	3.7	56

#	Article	IF	CITATIONS
73	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
74	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	1.6	83
75	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ÂE/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, 61-69.	2.8	63
76	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open, 2019, 4, e000491.	4.5	140
77	Prophylaxis and Management of Skin Toxicities. Breast Care, 2019, 14, 72-77.	1.4	15
78	Susceptibilityâ€weighted imaging in malignant melanoma brain metastasis. Journal of Magnetic Resonance Imaging, 2019, 50, 1251-1259.	3.4	11
79	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. European Journal of Cancer, 2019, 110, 11-20.	2.8	44
80	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	4.2	35
81	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	1.2	43
82	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	4.2	45
83	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	7.1	295
84	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	10.7	183
85	Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 917-924.	4.2	22
86	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1289-1296.	6.4	90
87	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α. Melanoma Research, 2018, 28, 204-210.	1.2	8
88	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG. European Journal of Cancer, 2018, 96, 34-43.	2.8	97
89	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	6.4	34
90	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine, 2018, 7, 95-104.	2.8	16

#	Article	IF	CITATIONS
91	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 175-182.	4.2	90
92	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 376-383.	6.4	160
93	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	1.6	431
94	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics, 2018, 8, 76.	2.6	23
95	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21
96	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. European Journal of Cancer, 2018, 104, 239-242.	2.8	43
97	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	7.1	1,625
98	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474.	4.8	174
99	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	4.2	22
100	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. PLoS ONE, 2018, 13, e0193946.	2.5	27
101	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. European Journal of Cancer, 2017, 75, 24-32.	2.8	162
102	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews, 2017, 57, 36-49.	7.7	257
103	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <u>Ta</u> dalafil in patients with metastatic Melanoma (TaMe). OncoImmunology, 2017, 6, e1326440.	4.6	74
104	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy, 2017, 40, 282-285.	2.4	28
105	Liquid Biopsy: Value for Melanoma Therapy?. Oncology Research and Treatment, 2017, 40, 430-434.	1.2	9
106	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Research, 2017, 27, 321-325.	1.2	46
107	Antiâ€PDâ€1 antibodies in metastatic uveal melanoma: a treatment option?. Cancer Medicine, 2017, 6, 1581-1586.	2.8	26
108	The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. Journal of Investigative Dermatology, 2017, 137, 261-264.	0.7	9

#	Article	IF	CITATIONS
109	PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Dermato-Venereologica, 2017, 97, 395-396.	1.3	39
110	Bone Formation in Cutaneous Nodules on the Leg: A Quiz. Acta Dermato-Venereologica, 2017, 97, 1263-1264.	1.3	0
111	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 3815-3822.	1.6	244
112	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hellenic Journal of Nuclear Medicine, 2017, 20, 251-253.	0.3	1
113	Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma. Journal of Cutaneous Pathology, 2016, 43, 367-371.	1.3	3
114	Rasterâ€scanned intensityâ€controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. Head and Neck, 2016, 38, E1445-51.	2.0	13
115	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clinical Nuclear Medicine, 2016, 41, 156-158.	1.3	5
116	Exanthematous cutaneous spread of metastatic urothelial carcinoma in a 69â€yearâ€old man. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1300-1302.	0.8	0
117	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	7.0	480
118	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 210-225.	2.8	490
119	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 190-209.	2.8	546
120	Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncology, The, 2016, 17, 1471-1472.	10.7	20
121	Immunotherapy of Melanoma. Oncology Research and Treatment, 2016, 39, 369-376.	1.2	14
122	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	27.0	1,140
123	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncolmmunology, 2016, 5, e1240859.	4.6	75
124	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Research, 2016, 6, 61.	2.5	29
125	Management of side effects of immune checkpoint blockade by antiâ€CTLAâ€4 and antiâ€PDâ€1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.8	63
126	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	27.8	1,243

#	Article	IF	CITATIONS
127	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	7.0	459
128	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	7.1	534
129	Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncolmmunology, 2016, 5, e1101207.	4.6	17
130	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews, 2016, 45, 7-18.	7.7	354
131	Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Annals of Oncology, 2016, 27, 1353-1354.	1.2	13
132	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. Oncotarget, 2016, 7, 36130-36137.	1.8	12
133	Two cases of intralymphatic histiocytosis following hip replacement. JDDG - Journal of the German Society of Dermatology, 2015, 13, 700-702.	0.8	2
134	In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: A feasibility study. Journal of Magnetic Resonance Imaging, 2015, 41, 1405-1412.	3.4	4
135	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Future Oncology, 2015, 11, 591-606.	2.4	16
136	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	12.0	143
137	RAS Mutations in Benign Epithelial Tumors Associated with BRAF Inhibitor Treatment of Melanoma. Journal of Investigative Dermatology, 2015, 135, 636-639.	0.7	6
138	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. New England Journal of Medicine, 2015, 372, 320-330.	27.0	4,795
139	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 386-396.	6.4	130
140	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	10.7	2,353
141	Solitary, Well-Circumscribed, Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 166.	0.6	1
142	Solitary, Well-Circumscribed Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 156.	0.6	0
143	Primary melanoma of the prostate: case report and review of the literature. BMC Urology, 2015, 15, 68.	1.4	14
144	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	12.6	2,275

#	Article	IF	CITATIONS
145	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 2014, 4, 94-109.	9.4	782
146	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹ I-BA52. Journal of Nuclear Medicine, 2014, 55, 9-14.	5.0	48
147	Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds. PLoS ONE, 2014, 9, e95723.	2.5	15
148	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 2014, 50, 406-410.	2.8	26
149	Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlentherapie Und Onkologie, 2014, 190, 1080-1081.	2.0	15
150	Comparison of molecular abnormalities in vulvar and vaginal melanomas. Modern Pathology, 2014, 27, 1386-1393.	5.5	70
151	Axillary accessory breast tissue – case report and review of literature. JDDG - Journal of the German Society of Dermatology, 2014, 12, 499-500.	0.8	3
152	Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus. Journal of Investigative Dermatology, 2013, 133, 1034-1042.	0.7	34
153	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Academic Radiology, 2013, 20, 423-429.	2.5	6
154	Varicella-Like Cutaneous Toxoplasmosis in a Patient with Aplastic Anemia. Journal of Clinical Microbiology, 2013, 51, 1341-1344.	3.9	7
155	Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma. Experimental Dermatology, 2013, 22, 757-759.	2.9	11
156	Necrolytic Migratory Erythema in a Patient with Neuroendocrine Carcinoma. Internal Medicine, 2013, 52, 151-152.	0.7	1
157	Malignant Melanoma S3-Guideline "Diagnosis, Therapy and Follow-up of Melanoma― JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.8	122
158	Compression Treatment of Ear Keloids by a Modified Oyster Splint Technique. , 2013, , 499-505.		0
159	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
160	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM) Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	1.6	14
161	lpilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients Journal of Clinical Oncology, 2012, 30, e19031-e19031.	1.6	0
162	Psychosomatic or allergic symptoms? High levels for somatization in patients with drug intolerance. Journal of Dermatology, 2011, 38, 959-965.	1.2	22

#	Article	IF	CITATIONS
163	Promising Results from a Pilot Study on Compression Treatment of Ear Keloids. Journal of Cutaneous Medicine and Surgery, 2011, 15, 130-136.	1.2	17
164	Phenol Chemical Matricectomy Is Less Painful, with Shorter Recovery Times but Higher Recurrence Rates, Than Surgical Matricectomy: A Patient's View. Dermatologic Surgery, 2010, 36, 1294-1299.	0.8	21
165	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	27.0	13,065
166	Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clinical Cancer Research, 2009, 15, 5208-5215.	7.0	168
167	Predicting tooth color from facial features and gender: Results from a white elderly cohort. Journal of Prosthetic Dentistry, 2008, 99, 101-106.	2.8	22
168	STAT5 contributes to antiapoptosis in melanoma. Melanoma Research, 2008, 18, 378-385.	1.2	34
169	Treatment of Ear Keloids by Compression, Using a Modified Oyster-Splint Technique. Dermatologic Surgery, 2007, 33, 208-212.	0.8	14
170	STAT5 Contributes to Interferon Resistance of Melanoma Cells. Current Biology, 2005, 15, 1629-1639.	3.9	56
171	Serological Immunomarkers in Cutaneous T Cell Lymphoma. Dermatology, 2004, 209, 296-300.	2.1	30